A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2011
11/22/2011	US8062626 Ethanolic solutions; shelf life; nebulizer metering device; free of ozone damaging materials
11/22/2011	CA2666090C Use of nicotinic acid adenine dinucleotide phosphate or derivative thereof as agent for treating type-2 diabetes
11/22/2011	CA2664720C Vitamin d derivatives
11/22/2011	CA2662278C Methods and compositions for increasing patient tolerability during myocardial imaging methods
11/22/2011	CA2653830C 6-(heterocycle-substituted benzyl)-4-oxoquinoline compound and use of the same as hiv integrase inhibitor
11/22/2011	CA2644750C Transdermal patch containing rasagiline for treatment or prophylaxis of nervous system disease and its preparation process
11/22/2011	CA2641713C Hydrate forms of amg706
11/22/2011	CA2620123C Methods for treating and monitoring inflammation and redox imbalance in cystic fibrosis
11/22/2011	CA2606353C Alpha-methyl amino acid derivatives
11/22/2011	CA2571760C New 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17.beta.-hydroxysteroid dehydrogenase type 1
11/22/2011	CA2558509C Tetrahydropyridoindole derivatives
11/22/2011	CA2546441C Novel compounds
11/22/2011	CA2529992C Glycoside-containing liposome
11/22/2011	CA2528223C Colchicoside analogues
11/22/2011	CA2524401C Thiazole derivatives as inhibitors of phosphatidylinositol 3-kinase
11/22/2011	CA2524023C Use of phenoxyacetic acid derivatives for treating hyperactive bladder
11/22/2011	CA2517371C Method for the production of flavonoid-containing compositions and their use
11/22/2011	CA2515546C Pyrrolidine derivatives as oxytocin antagonists
11/22/2011	CA2513655C Use of tryptanthrin compounds for immune potentiation
11/22/2011	CA2510807C Inhibitors of tace
11/22/2011	CA2509151C Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone
11/22/2011	CA2502439C Prostaglandin compounds for the treatment of obesity
11/22/2011	CA2493940C Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
11/22/2011	CA2490243C Aminoalkylphenols, methods of using and making the same
11/22/2011	CA2489902C Thiazole derivatives as phosphodiesterase iv inhibitors
11/22/2011	CA2489730C Use of mglur5 antagonists for the treatment of gerd
11/22/2011	CA2486917C Topically applicable pharmaceutical preparation containing roflumilast
11/22/2011	CA2486007C Delivery of nucleic acid-like compounds
11/22/2011	CA2484395C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
11/22/2011	CA2480452C Thioxanthine derivatives as myeloperoxidase inhibitors
11/22/2011	CA2473874C A composition for treating neurocerebrovascular disorders
11/22/2011	CA2471974C Quinazolinone derivatives and their use as cb agonists
11/22/2011	CA2471262C Pyrido(2,1-a)isoquinoline derivatives as dpp-iv inhibitors
11/22/2011	CA2468707C The use of indigestible oligosaccharides to improve the health and productivity of ruminant animals
11/22/2011	CA2465360C Catamenial device having antibacterial properties
11/22/2011	CA2464089C Stenoprophiluric matrices, and methods of making and using the same
11/22/2011	CA2456025C An implantable and sealable system for unidirectional delivery of therapeutic agents to tissues
11/22/2011	CA2449312C Methods for the treatment of nail fungus and other microbial and mycotic conditions and compositions useful therefor
11/22/2011	CA2420893C Method of obtaining a hydroxytyrosol-rich composition from vegetation water
11/22/2011	CA2416631C Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses
11/22/2011	CA2375975C Pyrithione biocides enhanced by silver, copper, or zinc ions
11/22/2011	CA2372511C Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/22/2011	CA2352324C Derivatives of (-)-venlafaxine and methods of preparing and using the same
11/22/2011	CA2344989C Health food products
11/22/2011	CA2257826C Helicobacter pylori adhesin binding group antigen
11/22/2011	CA2233620C Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies as antiinflammatory agents
11/21/2011	CA2740507A1 Drug coated expandable devices
11/20/2011	CA2704971A1 Embolizing sclerosing hydrogel
11/19/2011	CA2739131A1 Antibiotic coating containing at least one humectant
11/17/2011	WO2011143665A1 Treatment methods
11/17/2011	WO2011143646A1 Fused bicyclic kinase inhibitors
11/17/2011	WO2011143645A1 Fused bicyclic kinase inhibitors
11/17/2011	WO2011143640A2 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
11/17/2011	WO2011143613A1 Yeast cell wall components and detection thereof
11/17/2011	WO2011143608A1 Antisense modulation of interleukins 17 and 23 signaling
11/17/2011	WO2011143593A1 Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
11/17/2011	WO2011143590A1 Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
11/17/2011	WO2011143579A2 Cancer prevention and treatment methods based on dietary polyamine content
11/17/2011	WO2011143559A2 Compositions and methods which modulate g-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis
11/17/2011	WO2011143534A1 Methods for the treatment of psychiatric disorders
11/17/2011	WO2011143526A2 Topical peripheral neuro-affective (tpna) therapy
11/17/2011	WO2011143503A2 Tetracycline compositions
11/17/2011	WO2011143497A1 Aminoglycoside derivatives
11/17/2011	WO2011143495A1 Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
11/17/2011	WO2011143484A1 A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent
11/17/2011	WO2011143479A1 Injectable parasiticidal formulations of levamisole and macrocyclic lactones
11/17/2011	WO2011143466A1 Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
11/17/2011	WO2011143459A1 Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases
11/17/2011	WO2011143457A2 Compositions and methods for treating or preventing atrial fibrillation
11/17/2011	WO2011143444A2 Diphenylbutypiperidine autophagy inducers
11/17/2011	WO2011143442A1 A method of treating multiple sclerosis with adenosine receptor agonists
11/17/2011	WO2011143430A1 Indazole inhibitors of kinase
11/17/2011	WO2011143426A1 Compounds useful as inhibitors of atr kinase
11/17/2011	WO2011143422A1 2 -aminopyridine derivatives useful as inhibitors of atr kinase
11/17/2011	WO2011143399A1 Compounds useful as inhibitors of atr kinase
11/17/2011	WO2011143366A1 Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
11/17/2011	WO2011143365A1 Nitrogen heterocyclic compounds useful as pde10 inhibitors
11/17/2011	WO2011143332A1 Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity
11/17/2011	WO2011143314A1 Compositions and methods for reducing proliferation and viability of lymphoblastoid cells
11/17/2011	WO2011143296A1 Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
11/17/2011	WO2011143271A2 Therapeutic liposomes and methods for producing and using the same
11/17/2011	WO2011143262A2 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
11/17/2011	WO2011143201A2 Ratiometric combinatorial drug delivery
11/17/2011	WO2011143163A1 Substituted n-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof
11/17/2011	WO2011143162A1 Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
11/17/2011	WO2011143161A1 Substituted n-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
11/17/2011	WO2011143160A2 Metabolic inhibitor against tumors having an idh mutation
11/17/2011	WO2011143155A1 Substituted n-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
11/17/2011	WO2011143150A1 Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
11/17/2011	WO2011143148A1 Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
11/17/2011	WO2011143147A1 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
11/17/2011	WO2011143145A1 Substituted n-alkyl and n-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
11/17/2011	WO2011143129A1 Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
11/17/2011	WO2011143120A1 Alcoholres i stant metoprolol - containing extended - release oral dosage forms
11/17/2011	WO2011143119A1 Alcohol-resistant extended release dosage forms comprising venlafaxine
11/17/2011	WO2011143106A1 Bi - functional pyrazolopyridine compounds
11/17/2011	WO2011143105A1 Bifunctional quinoline derivatives
11/17/2011	WO2011143057A1 Novel prolylcarboxypeptidase inhibitors
11/17/2011	WO2011143033A1 Pyrimidine compounds that inhibit anaplastic lymphoma kinase
11/17/2011	WO2011142795A1 Novel analogs of curcumin and methods of use

1 ... 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 ... 7860